NEW YORK: Braeburn Pharmaceuticals has hired MSLGroup to support the planning and launch of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence in adult patients.
Earlier this month, the US Food and Drug Administration indicated that it would give the product's regulatory application an expedited review.
Jim Weinrebe, EVP at SchwartzMSL Boston, is leading work on the account. Beyond confirming the win, he could say little about the work the firm is doing on the account while the product is under review. Weinrebe said pitching for the business was a “substantial” endeavor.
The potential market for the product is up to 2.3 million people in the US, according to Titan Pharmaceuticals, which signed a license agreement with Braeburn last month. That represents the number of people who are addicted to opoids in America, according to Titan.
Titan expects to receive up to $50 million if Probuphone is approved by the FDA, and tens of millions of dollars more if regulatory milestones for extraneous indications like chronic pain are reached.
Apple Tree Partners, a life sciences venture capital firm, owns Braeburn Pharmaceuticals. Representatives from the company declined to comment on account.
In spring 2012, Retina Implant AG, a German developer of sub-retinal implants for partially sighted and blind patients, teamed with SchwartzMSL Boston to build buzz for its technology in the US.